The stock's fall snapped a two-day winning streak.

This was the stock's second consecutive day of gains.

Catalyst Pharmaceuticals' current stock price only assumes historical momentum for existing drug portfolio continues, undervaluing future upside potentials. CPRX stock's upside potential is driven ...

Catalyst Pharmaceuticals' Firdapse delivers strong growth with a 37% CAGR. Click here to find out why CPRX stock is a Hold.

Shares of drugmaker Catalyst Pharmaceuticals (NASDAQ: CPRX) are up a little more than 8% as of midday on Thursday, down slightly from an intraday peak gain of nearly 13%. The company's fourth-quarter ...

Total Revenues of $491.7 Million, Marking Another Year of Record GrowthFull Year 2024 Total Revenues Grew 23.5% YoY, Driven by ...

Stephens analyst Sudan Loganathan raised the firm’s price target on Catalyst Pharmaceuticals (CPRX) to $40 from $33 and keeps an Overweight ...

Handelsbanken Fonder AB grew its holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX – Free Report) by 2.9% in the 4th ...

Catalyst Pharmaceuticals, Inc. is a commercial-stage, patient-centric biopharmaceutical company, which focuses on in-licensing, developing, and commercializing novel medicines for patients living ...

Catalyst Pharmaceuticals reported 2024 revenues of $491.7 million, projecting growth to $545-$565 million in 2025. Catalyst Pharmaceuticals, Inc. reported a record total revenue of $491.7 million ...

Catalyst Pharmaceuticals, Inc. has a 52 week low of $14.47 and a 52 week high of $24.64. The firm has a market cap of $2.51 billion, a P/E ratio of 17.52, a P/E/G ratio of 3.31 and a beta of 0.84 ...

On Tuesday, 11 March 2025, Catalyst Pharmaceuticals (NASDAQ: CPRX) presented at the Barclays 27th Annual Global Healthcare Conference. The company highlighted its strategic focus on organic growth ...